Profusa, Inc. (NVACW)

Profusa is building a new category of medical device: tiny sensors that live under the skin and continuously report what is happening inside your body. Implant a sensor the size of a few grains of salt, and it can measure your glucose level every few seconds without drawing blood, send that data wirelessly to a device or your phone, and do this for months or even years before needing replacement. For people managing diabetes, this is transformative — no more fingerstick tests, no more the guessing game of whether your blood sugar is rising or falling right now. For the broader market in health monitoring, if the sensors can be made cheaply and reliably, they represent a shift from episodic blood tests to continuous insight into what is happening in your body in real time.

Profusa’s central innovation is a biocompatible material called an aqueous polymer that forms a thin scaffold around the sensor, allowing glucose molecules and other biomolecules to pass through while protecting the sensor from the body’s immune response. The sensor itself contains enzymes that react with glucose and produce a small electrical signal proportional to the glucose concentration. That signal is transmitted wirelessly to a receiver worn on the skin or carried in a pocket. The company has spent over a decade proving that such a sensor can sit under the skin for extended periods without triggering rejection or degradation.

The company’s history reflects the long, expensive path to medical-device approval. Founded in 2010, Profusa spent years developing the fundamental science: proving the polymer could keep the sensor alive in the hostile chemical environment of the body, demonstrating that the sensor was accurate and stable over weeks, and working with regulatory agencies to define what data would be needed to support approval. The company has raised capital from venture investors, strategic partnerships with larger medical-device companies, and strategic collaborations with diagnostics firms. Progress has been incremental — not because the team is slow, but because the stakes are high (implantable devices must be extraordinarily safe and reliable) and regulators are appropriately cautious.

The regulatory path for implantable biosensors is complex. Profusa’s first target was continuous glucose monitoring, a large and underserved market. People with diabetes currently use one of two main tools: fingerstick tests (accurate but inconvenient, done only several times a day) or continuous glucose monitors that sit on the skin and have a tiny sensor that pierces into subcutaneous tissue (more continuous than fingersticks but the sensor needs replacement every seven to fourteen days, is external, and can become uncomfortable). An implantable sensor that worked for months would be dramatically better. The company pursued FDA approval for a continuous glucose monitor under the framework for Class III (high-risk) medical devices, which requires clinical trial data showing the device is safe and effective.

Beyond glucose, Profusa and others in the biosensor space see a much larger market: continuous monitoring of other biomolecules relevant to health. Lactate, which indicates metabolic demand and tissue oxygenation, is valuable in critical care and athletic performance. Other targets include ketones, electrolytes, and tumor markers. If the core technology can be extended to sense multiple analytes reliably, the applications multiply. In theory, a person could have multiple implanted sensors, each reporting a different biomarker, creating a real-time dashboard of internal chemistry.

The economics of biosensor companies depend on regulatory approval, manufacturing scale, and reimbursement. A single implantable sensor might cost hundreds of dollars to manufacture initially, but if volumes reach millions of units per year, economies of scale could drive per-unit costs down sharply. The reimbursement question is critical: will insurance companies and patients pay for implantable sensors? For diabetes management, continuous glucose monitors have shown value and are largely reimbursed. For other applications, reimbursement is less clear. If a patient needs a sensor replaced every month, the annual cost must be justifiable relative to the benefit.

Manufacturing is another hurdle. Implantable devices require sterile production, quality control that ensures every unit is identical and biocompatible, and supply chains that don’t exist yet at scale. Profusa has had to build or partner with manufacturers capable of mass-producing tiny sensors to the precision required. As demand grows, the company will either scale its own manufacturing or license the technology to larger medical-device companies with existing production capacity.

The competitive landscape in continuous glucose monitoring is dominated by established names like Dexcom and Abbott, which have FDA-approved products, commercial scale, and insurance reimbursement relationships. Profusa’s advantage, if it executes, is the implantable format — potentially years of wear without replacement, completely under the skin, and no daily adhesive changes. That advantage only matters if the sensor works reliably, is reimbursed, and can be manufactured at scale.

The founder and operator culture at Profusa has been central to its strategy. The company’s leadership has pursued a patient, evidence-driven path, resisting pressure to rush to market before the technology was ready. That approach has meant slower progress than some competitors, but it has also meant avoiding the trap of launching a product that fails in real-world conditions, which would set the technology back years. The culture emphasizes the scientific rigor required to build an implantable device that will live in people’s bodies and on which they will rely for medical decisions.

Long-term risks include competitive entries (large medical-device companies building their own implantable sensors), regulatory setbacks (if clinical data don’t support approval), and the question of whether the market will embrace implanted devices or prefer external options despite their inconvenience. The company also faces the capital intensity of medical-device development and manufacturing, which means it has needed and will continue to need significant capital to reach profitability.

Understanding Profusa requires reading its clinical trial data and regulatory submissions carefully. The company has published studies in peer-reviewed journals showing sensor accuracy and longevity in human subjects. The FDA approval documents (available in the company’s SEC filings and the FDA’s online database) detail exactly what the device is cleared to do and what limitations regulators imposed. The quarterly earnings calls provide updates on trial progress, regulatory timelines, and partnerships. For investors, this is a long-term, technology-driven story where the next catalyst is regulatory approval or expansion into new biomarkers, not quarterly earnings surprises.